Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Oncology Letters|March 31, 2017
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, et al.
BMC Cancer|March 28, 2013
Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancerMegumi Ishiguro, Kenjiro Kotake, Genichi Nishimura, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2014
Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trialTakashi Tsuchiya, Sotaro Sadahiro, Kazuaki Sasaki, et al.
Annals of Surgical Oncology|September 18, 2016
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal CancerMasato Kataoka, Mitsuro Kanda, Kiyoshi Ishigure, et al.
BMC Cancer|February 16, 2022
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)Sotaro Sadahiro, Kazuhiro Sakamoto, Takashi Tsuchiya, et al.
Clinical Colorectal Cancer|June 13, 2015
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201)Sotaro Sadahiro, Satoshi Morita, Kazuaki Sasaki, et al.
International Journal of Clinical Oncology|January 13, 2017
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancerTakeshi Suto, Megumi Ishiguro, Chikuma Hamada, et al.
International Journal of Clinical Oncology|June 4, 2024
Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)Yutaka Ogata, Sotaro Sadahiro, Kazuhiro Sakamoto, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|June 6, 2013
Quality of gastric cancer care in designated cancer care hospitals in JapanTakahiro Higashi, Fumiaki Nakamura, Yasuhiro Shimada, et al.
Cancer Immunology, Immunotherapy : CII|April 16, 2022
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapyYasuhiro Nagata, Shinichi Kageyama, Takeshi Ishikawa, et al.
Pageof 5